Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19
dc.contributor.author | García Ríos, Estéfani | |
dc.contributor.author | Leivas, Alejandra | |
dc.contributor.author | Mancebo, Francisco J. | |
dc.contributor.author | Sánchez Vega, Laura | |
dc.contributor.author | Lanzarot, Diego | |
dc.contributor.author | Aguado García, José María | |
dc.contributor.author | Martínez López, Joaquín | |
dc.contributor.author | Paciello, María Liz | |
dc.contributor.author | Pérez Romero, Pilar | |
dc.date.accessioned | 2023-06-22T10:45:42Z | |
dc.date.available | 2023-06-22T10:45:42Z | |
dc.date.issued | 2022-03-09 | |
dc.description.abstract | In order to demonstrate the feasibility of preparing clinical-grade SARS-CoV-2-specific T-cells from convalescent donors and the ability of these cells to neutralize the virus in vitro, we used blood collected from two COVID-19 convalescent donors (before and after vaccination) that was stimulated with specific SARS-CoV-2 peptides followed by automated T-cell isolation using the CliniMacs Prodigy medical device. To determine cytotoxic activity, HEK 293T cells were transfected to express the SARS-CoV-2 M protein, mimicking SARS-CoV-2 infection. We were able to quickly and efficiently isolate SARS-CoV-2-specific T lymphocytes from both donors before and after they received the Pfizer-BioNTech vaccine. Althoughbefore vaccination, the final product contained up to 7.42% and 30.19% of IFN-γ+ CD3+ T-cells from donor 1 and donor 2, respectively, we observed an enrichment of the IFN-γ+ CD3+ T-cells after vaccination, reaching 70.47% and 42.59%, respectively. At pre-vaccination, the isolated SARS-CoV-2-specific T-cells exhibited cytotoxic activity that was significantly higher than that of unstimulated controls (donor 2: 15.41%, p-value 3.27 × 10−3). The cytotoxic activity of the isolated SARS-CoV-2-specific T-cells also significantly increased after vaccination (donor 1: 32.71%, p-value 1.44 × 10−5; donor 2: 33.38%, p-value 3.13 × 10−6). In conclusion, we demonstrated that SARS-CoV-2-specific T-cells can quickly and efficiently be stimulated from the blood of convalescent donors using SARS-CoV-2-specific peptides followed by automated isolation. Vaccinated convalescent donors have a higher percentage of SARS-CoV-2-specific T-cells and may be more suitable as donors. Although further studies are needed to assess the clinical utility of the functional isolated SARS-CoV-2-specific T-cells in patients, previous studies using the same stimulation and isolation methods applied to other pathologies support this idea. | en |
dc.description.department | Depto. de Medicina | |
dc.description.faculty | Fac. de Medicina | |
dc.description.refereed | TRUE | |
dc.description.sponsorship | Ministerio de Ciencia, Innovación y Universidades (España)/Fondo Europeo de Desarrollo Regional | |
dc.description.sponsorship | Instituto de Salud Carlos III | |
dc.description.sponsorship | Universidad Complutense de Madrid/Comunidad de Madrid | |
dc.description.status | pub | |
dc.eprint.id | https://eprints.ucm.es/id/eprint/72840 | |
dc.identifier.citation | García Ríos, E., Laivas, A., Mancebo, F. J. et al. «Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19». Biomedicines, vol. 10, n.o 3, marzo de 2022, p. 630. DOI.org (Crossref), https://doi.org/10.3390/biomedicines10030630. | |
dc.identifier.doi | 10.3390/biomedicines10030630 | |
dc.identifier.issn | 2227-9059 | |
dc.identifier.officialurl | https://doi.org/10.3390/biomedicines10030630 | |
dc.identifier.relatedurl | https://www.mdpi.com/2227-9059/10/3/630/htm | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/71610 | |
dc.issue.number | 3 | |
dc.journal.title | Biomedicines | |
dc.language.iso | eng | |
dc.page.initial | 630 | |
dc.publisher | MPDI | |
dc.relation.projectID | (REIPI RD16/0016) | |
dc.relation.projectID | (COVID-19 Research Call COV20/00181); (F18III/00013); (CD18CIII/00007) | |
dc.relation.projectID | REACT-EU | |
dc.rights | Atribución 3.0 España | |
dc.rights.accessRights | open access | |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject.keyword | SARS-CoV-2 | |
dc.subject.keyword | T-lymphocytes | |
dc.subject.keyword | Cytotoxicity | |
dc.subject.keyword | M protein | |
dc.subject.ucm | Inmunología | |
dc.subject.unesco | 2412 Inmunología | |
dc.title | Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19 | en |
dc.type | journal article | |
dc.volume.number | 10 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 6f2765d7-77be-4ef3-98a1-3d16f6d8510a | |
relation.isAuthorOfPublication | 5d58b324-f60e-4598-941b-4a07291634a9 | |
relation.isAuthorOfPublication.latestForDiscovery | 6f2765d7-77be-4ef3-98a1-3d16f6d8510a |
Download
Original bundle
1 - 1 of 1